Condition: Hypercholesterolaemia · Sponsor: Novartis Pharmaceuticals
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Corrientes, Argentina | Recruiting |
| Novartis Investigative Site | Salvador, Estado de Bahia, Brazil | Recruiting |
| Novartis Investigative Site | Belo Horizonte, Minas Gerais, Brazil | Recruiting |
| Novartis Investigative Site | Belo Horizonte, Minas Gerais, Brazil | Recruiting |
| Novartis Investigative Site | Campo Largo, Paraná, Brazil | Recruiting |
| Novartis Investigative Site | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| Novartis Investigative Site | Blumenau, Santa Catarina, Brazil | Withdrawn |
| Novartis Investigative Site | São José, Santa Catarina, Brazil | Recruiting |
| Novartis Investigative Site | São José, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | Campina Gde Do Sul, Brazil | Recruiting |
| Novartis Investigative Site | Salvador, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06501443